Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes Post hoc analysis of an open-label, randomised, phase 3 trial

被引：0
|
作者：
Schuerfeld, Robin [1 ]
机构：
[1] Univ Klinikum Leipzig, Med Klin 3, Klin & Poliklin Endokrinol Nephrol Rheumatol Bere, Liebigstr 20, D-04103 Leipzig, Germany
来源：
DIABETOLOGIE | 2023年 / 19卷 / 02期
关键词：
D O I：
10.1007/s11428-023-01002-x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：205 / 207
页数：3
相关论文
共 50 条
  • [1] Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial
    Heerspink, Hiddo J. L.
    Sattar, Naveed
    Pavo, Imre
    Haupt, Axel
    Duffin, Kevin L.
    Yang, Zhengyu
    Wiese, Russell J.
    Tuttle, Katherine R.
    Cherney, David Z. I.
    LANCET DIABETES & ENDOCRINOLOGY, 2022, 10 (11): : 774 - 785
  • [2] Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
    Del Prato, Stefano
    Kahn, Steven E.
    Pavo, Imre
    Weerakkody, Govinda J.
    Yang, Zhengyu
    Doupis, John
    Aizenberg, Diego
    Wynne, Alan G.
    Riesmeyer, Jeffrey S.
    Heine, Robert J.
    Wiese, Russell J.
    LANCET, 2021, 398 (10313): : 1811 - 1824
  • [3] Effekte von Tirzepatid im Vergleich zu Insulin Glargin auf die Nierenfunktion bei Typ-2-DiabetesPost-hoc-Analyse einer offenen, randomisierten Phase-3-StudieEffects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetesPost hoc analysis of an open-label, randomised, phase 3 trial
    Robin Schürfeld
    Die Diabetologie, 2023, 19 (2) : 205 - 207
  • [4] Efficacy and Safety of LY2963016 Insulin Glargine in Chinese Patients with Type 1 Diabetes Previously Treated with Insulin Glargine (Lantus®): a Post Hoc Analysis of a Randomized, Open-Label, Phase 3 Trial
    Xiang Yan
    Chen Feng
    Ying Lou
    Zhiguang Zhou
    Diabetes Therapy, 2022, 13 : 1161 - 1174
  • [5] Efficacy and Safety of LY2963016 Insulin Glargine in Chinese Patients with Type 1 Diabetes Previously Treated with Insulin Glargine (Lantus®): a Post Hoc Analysis of a Randomized, Open-Label, Phase 3 Trial
    Yan, Xiang
    Feng, Chen
    Lou, Ying
    Zhou, Zhiguang
    DIABETES THERAPY, 2022, 13 (06) : 1161 - 1174
  • [6] Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial
    Diamant, Michaela
    Van Gaal, Luc
    Guerci, Bruno
    Stranks, Stephen
    Han, Jenny
    Malloy, Jaret
    Boardman, Marilyn K.
    Trautmann, Michael E.
    LANCET DIABETES & ENDOCRINOLOGY, 2014, 2 (06): : 464 - 473
  • [7] Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial
    Aschner, Pablo
    Chan, Juliana
    Owens, David R.
    Picard, Sylvie
    Wang, Edward
    Dain, Marie-Paule
    Pilorget, Valerie
    Echtay, Akram
    Fonseca, Vivian
    LANCET, 2012, 379 (9833): : 2262 - 2269
  • [8] Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
    Tuttle, Katherine R.
    Lakshmanan, Mark C.
    Rayner, Brian
    Busch, Robert S.
    Zimmermann, Alan G.
    Woodward, D. Bradley
    Botros, Fady T.
    LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (08): : 605 - 617
  • [9] Efficacy and safety of LY2963016 insulin glargine versus insulin glargine (Lantus) in Chinese adults with type 2 diabetes: A phase III, randomized, open-label, controlled trial
    Feng, Wenhuan
    Chen, Wei
    Jiang, Shan
    Du, Liying
    Zhu, Dalong
    DIABETES OBESITY & METABOLISM, 2021, 23 (08): : 1786 - 1794
  • [10] Effects of tirzepatide versus insulin glargine 100 U/mL on kidney outcomes in participants with type 2 diabetes in SURPASS-4
    Heerspink, H. J. L.
    Sattar, N.
    Pavo, I.
    Haupt, A.
    Duffin, K. L.
    Yang, Z.
    Wiese, R. J.
    Tuttle, K. R.
    Cherney, D. Z. I.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S316 - S316
12345